Company: AGIO
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0001439222-25-000036
Chunk: 65

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 65
---
Item 1.        Financial Statements (Unaudited)

AGIOS PHARMACEUTICALS, INC.

Condensed Consolidated Balance Sheets 

(Unaudited)(In thousands, except share and per share data)March 31,2025December 31,2024AssetsCurrent assets:Cash and cash equivalents$78,964 $76,247 Marketable securities814,411 817,463 Accounts receivable, net3,344 4,109 Inventory 29,605 27,616 Prepaid expenses and other current assets42,292 40,165 Total current assets968,616 965,600 Marketable securities531,253 638,321 Operating lease assets39,861 42,879 Property and equipment, net11,067 11,675 Other non-current assets4,721 4,724 Total assets$1,555,518 $1,663,199 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$13,726 $16,643 Accrued expenses20,761 46,861 Income taxes payable683 871 Operating lease liabilities17,196 16,781 Total current liabilities52,366 81,156 Operating lease liabilities, net of current portion35,744 40,207 Other non-current liabilities880 880 Total liabilities88,990 122,243 Stockholders’ equity:Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at March 31, 2025 and December 31, 2024— — Common stock, $0.001 par value; 125,000,000 shares authorized; 74,103,192 shares issued and 57,886,781 shares outstanding at March 31, 2025, and 73,372,696 shares issued and 57,156,285 shares outstanding at December 31, 202474 73 Additional paid-in capital2,506,788 2,493,811 Accumulated other comprehensive income (loss)365 (1,518)Treasury stock, at cost (16,216,411 shares at March 31, 2025 and December 31, 2024)(802,486)(802,486)Accumulated deficit(238,213)(148,924)Total stockholders’ equity1,466,528